Drugs / AC176
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05673109 | Feb → Oct 2023 | castration-resistant prostate carcinoma | Accutar Biotechnology Inc | Terminated | No outcome recorded |
| Phase 1 | NCT05241613 | Mar 2022 → Mar 2024 | castration-resistant prostate carcinoma | Accutar Biotechnology Inc | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05673109 ↗ |
| Route | Oral | “AC176 will be given orally (PO)” NCT05241613 ↗ |
| Target | AR | “Androgen Receptor (AR) degrader” NCT05241613 ↗ |